109 related articles for article (PubMed ID: 12971387)
1. American Association for Cancer Research--94th Annual Meeting. New compounds. 11-14 July 2003, Washington, DC, USA.
Mackay J; Williams L
IDrugs; 2003 Aug; 6(8):733-5. PubMed ID: 12971387
[No Abstract] [Full Text] [Related]
2. Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families.
Glaser KB; Li J; Marcotte PA; Magoc TJ; Guo J; Reuter DR; Tapang P; Wei RQ; Pease LJ; Bui MH; Chen Z; Frey RR; Johnson EF; Osterling DJ; Olson AM; Bouska JJ; Luo Y; Curtin ML; Donawho CK; Michaelides MR; Tse C; Davidsen SK; Albert DH
J Pharmacol Exp Ther; 2012 Dec; 343(3):617-27. PubMed ID: 22935731
[TBL] [Abstract][Full Text] [Related]
3. American association for cancer research--96th annual meeting. Kinases.
Phillips T; Collins T; Davies J
IDrugs; 2005 Jun; 8(6):458-60. PubMed ID: 15906186
[No Abstract] [Full Text] [Related]
4. Validating Stat3 in cancer therapy.
Darnell JE
Nat Med; 2005 Jun; 11(6):595-6. PubMed ID: 15937466
[No Abstract] [Full Text] [Related]
5. American Association for Cancer Research--94th Annual Meeting. Investigational drugs. 11-14 July 2003, Washington, DC, USA.
Mackay J; Williams L
IDrugs; 2003 Aug; 6(8):736-8. PubMed ID: 12971388
[No Abstract] [Full Text] [Related]
6. Cucurbitacin Q: a selective STAT3 activation inhibitor with potent antitumor activity.
Sun J; Blaskovich MA; Jove R; Livingston SK; Coppola D; Sebti SM
Oncogene; 2005 May; 24(20):3236-45. PubMed ID: 15735720
[TBL] [Abstract][Full Text] [Related]
7. STAT proteins: novel molecular targets for cancer drug discovery.
Turkson J; Jove R
Oncogene; 2000 Dec; 19(56):6613-26. PubMed ID: 11426647
[TBL] [Abstract][Full Text] [Related]
8. Identification of a high-affinity phosphopeptide inhibitor of Stat3.
Ren Z; Cabell LA; Schaefer TS; McMurray JS
Bioorg Med Chem Lett; 2003 Feb; 13(4):633-6. PubMed ID: 12639546
[TBL] [Abstract][Full Text] [Related]
9. [Effect of nocodazole on the activation of transcription factors STAT1 and STAT3 in A431 cells].
Vasilenko KP; Burova EB; Vinogradova NA; Nikol'skiĭ NN
Tsitologiia; 2004; 46(12):1025-9. PubMed ID: 15747831
[TBL] [Abstract][Full Text] [Related]
10. Bifunctional recombinant proteins in cancer therapy: cell penetrating peptide aptamers as inhibitors of growth factor signaling.
Buerger C; Groner B
J Cancer Res Clin Oncol; 2003 Dec; 129(12):669-75. PubMed ID: 13680379
[TBL] [Abstract][Full Text] [Related]
11. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice.
Blaskovich MA; Sun J; Cantor A; Turkson J; Jove R; Sebti SM
Cancer Res; 2003 Mar; 63(6):1270-9. PubMed ID: 12649187
[TBL] [Abstract][Full Text] [Related]
12. Head and Neck Cancer--Sixth International Conference. 7-11 August 2004, Washington, DC, USA.
Susman E
IDrugs; 2004 Oct; 7(10):917-9. PubMed ID: 15478015
[No Abstract] [Full Text] [Related]
13. In vivo antitumor efficacy of STAT3 blockade using a transcription factor decoy approach: implications for cancer therapy.
Xi S; Gooding WE; Grandis JR
Oncogene; 2005 Feb; 24(6):970-9. PubMed ID: 15592503
[TBL] [Abstract][Full Text] [Related]
14. Activation of Stat3 preassembled with platelet-derived growth factor beta receptors requires Src kinase activity.
Wang YZ; Wharton W; Garcia R; Kraker A; Jove R; Pledger WJ
Oncogene; 2000 Apr; 19(17):2075-85. PubMed ID: 10815799
[TBL] [Abstract][Full Text] [Related]
15. 94th annual meeting of the American Association for Cancer Research Washington, DC--July 11-14, 2003.
Lobert S
Oncol Nurs Forum; 2003; 30(5):741-2. PubMed ID: 12966928
[No Abstract] [Full Text] [Related]
16. Src and focal adhesion kinase as therapeutic targets in cancer.
Brunton VG; Frame MC
Curr Opin Pharmacol; 2008 Aug; 8(4):427-32. PubMed ID: 18625340
[TBL] [Abstract][Full Text] [Related]
17. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis.
Niu G; Wright KL; Huang M; Song L; Haura E; Turkson J; Zhang S; Wang T; Sinibaldi D; Coppola D; Heller R; Ellis LM; Karras J; Bromberg J; Pardoll D; Jove R; Yu H
Oncogene; 2002 Mar; 21(13):2000-8. PubMed ID: 11960372
[TBL] [Abstract][Full Text] [Related]
18. The nonsteroidal anti-inflammatory drug sulindac causes down-regulation of signal transducer and activator of transcription 3 in human oral squamous cell carcinoma cells.
Nikitakis NG; Hamburger AW; Sauk JJ
Cancer Res; 2002 Feb; 62(4):1004-7. PubMed ID: 11861373
[TBL] [Abstract][Full Text] [Related]
19. MedGenMed Hematology/Oncology conference report--translational research: any danger lurking in its wake? Highlights from the 2003 annual meeting of the American Association for Cancer Research; July 11-14, 2003; Washington, DC.
Mariani SM
MedGenMed; 2003 Aug; 5(3):34. PubMed ID: 14600670
[No Abstract] [Full Text] [Related]
20. Anti-angiogenic activity of thienopyridine derivative LCB03-0110 by targeting VEGFR-2 and JAK/STAT3 Signalling.
Kim BH; Lee Y; Yoo H; Cui M; Lee S; Kim SY; Cho JU; Lee H; Yang BS; Kwon YG; Choi S; Kim TY
Exp Dermatol; 2015 Jul; 24(7):503-9. PubMed ID: 25808463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
